Evaluation of induction of remission, intensification, and central nervous system prophylactic treatment in acute lymphoblastic leukemia.
D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000517:prevention & control* / Q000532:radiotherapy; D002648:Child; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007239:Infections / Q000209:etiology; D007278:Injections, Spinal; D007945:Leukemia, Lymphoid / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012075:Remission, Spontaneous
D004317:Doxorubicin; D008727:Methotrexate; D003630:Daunorubicin